| Dr Jonathan Charles Rock, MD | |
|
950 Medical Dr, Brigham City, UT 84302-4724 | |
| (435) 734-9471 | |
| Not Available |
| Full Name | Dr Jonathan Charles Rock |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 30 Years |
| Location | 950 Medical Dr, Brigham City, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104826700 | NPI | - | NPPES |
| 100207220C | Medicaid | OK | |
| 243328301 | Other | OK | INDIVIDUAL MEDICARE NUMBE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 5571577-1205 (Utah) | Primary |
| 2085R0202X | Radiology - Diagnostic Radiology | 19785 (Oklahoma) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Breast Center | 8325946072 | 2 |
News Archive
From the neurons that enable thought to the keratinocytes that make toenails grow-a complex canopy of sugar molecules, commonly known as glycans, envelop every living cell in the human body.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
It has been known for a long time that early risers work less efficiently at night than night owls do. But researchers from the Higher School of Economics and Oxford University have uncovered new and distinctive features between the night activities of these two types of individuals.
It is possible to determine which patients run a high risk of developing Alzheimer's disease and the dementia associated with it, even in patients with minimal memory impairment. This has been shown by recent research at the Sahlgrenska Academy, University of Gothenburg, Sweden.
› Verified 7 days ago
| Entity Name | The Breast Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215952023 PECOS PAC ID: 8325946072 Enrollment ID: O20031219000558 |
News Archive
From the neurons that enable thought to the keratinocytes that make toenails grow-a complex canopy of sugar molecules, commonly known as glycans, envelop every living cell in the human body.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
It has been known for a long time that early risers work less efficiently at night than night owls do. But researchers from the Higher School of Economics and Oxford University have uncovered new and distinctive features between the night activities of these two types of individuals.
It is possible to determine which patients run a high risk of developing Alzheimer's disease and the dementia associated with it, even in patients with minimal memory impairment. This has been shown by recent research at the Sahlgrenska Academy, University of Gothenburg, Sweden.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jonathan Charles Rock, MD Po Box 629, Ogden, UT 84402-0629 Ph: (580) 536-9300 | Dr Jonathan Charles Rock, MD 950 Medical Dr, Brigham City, UT 84302-4724 Ph: (435) 734-9471 |
News Archive
From the neurons that enable thought to the keratinocytes that make toenails grow-a complex canopy of sugar molecules, commonly known as glycans, envelop every living cell in the human body.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
It has been known for a long time that early risers work less efficiently at night than night owls do. But researchers from the Higher School of Economics and Oxford University have uncovered new and distinctive features between the night activities of these two types of individuals.
It is possible to determine which patients run a high risk of developing Alzheimer's disease and the dementia associated with it, even in patients with minimal memory impairment. This has been shown by recent research at the Sahlgrenska Academy, University of Gothenburg, Sweden.
› Verified 7 days ago